EZR-AS1: EZR-AS1 is an antisense long non-coding RNA (lncRNA) that has been studied in various cancer types. In breast cancer cells, knockdown of EZR-AS1 resulted in decreased nuclear expression of β-catenin, MYC, SOX4, and cyclin D1 [PMC6122301]. However, further research is needed to determine if EZR-AS1 is an independent prognostic factor [PMC6122301]. In cutaneous squamous cell carcinoma (cSCC) cells, EZR-AS1 expression was found to be significantly increased compared to normal skin cells [PMC7716411]. EZR-AS1 was found to facilitate the recruitment of SMYD3 to the SMYD3 binding site in the GC-rich region downstream of the EZR promoter. This recruitment led to increased SMYD3 concentration and trimethylation of H3K4 in the EZR gene [PMC10030596]. Additionally, EZR-AS1 was found to form a complex with RNA polymerase II and induce transcription of the EZR gene [PMC10030596]. However, the specific regulatory role and mechanism of lncRNA EZR-AS1 in colorectal cancer (CRC) remain unclear [PMC6851510]. Overall, these studies highlight the importance of understanding the role and function of lncRNA EZR-AS1 in different cancer types.